From next-generation cell therapies to neurotechnology, Chinese universities, hospitals and biotech companies are testing new ways to treat serious diseases. Some approaches are in human studies; others are early research. We follow them so you know what is being studied, what the evidence shows and what to ask your doctors.
These are research-stage developments, not treatments you can buy or book. Only a study’s own research team decides who can take part. Do not delay standard medical care while you explore an experimental option.
Researchers aim to program immune cells inside the body instead of in a laboratory. Safety, precision and lasting benefit are still being studied. NCT07859462 · Phase 1 · Not yet recruiting · checked 12 Nov 2026
Study record →CAR-NK and mutation-targeted TCR-T cells are being tested in selected cancers. Most studies need a matching tumour marker and have narrow eligibility. NCT07622940 · Phase 1/2 · Recruiting · checked 12 Nov 2026
Study record →Investigational vaccines use features of a person’s own tumour to train the immune system. These are small studies, not approved cancer vaccines. NCT06682117 · Phase not stated · Recruiting · checked 12 Nov 2026
Study record →Replacement islet cells are being tested in some people with very hard-to-control diabetes. Rejection, immune suppression and long-term safety remain major questions. NCT07503028 · Early phase 1 · Enrolling by invitation only · checked 12 Nov 2026
Study record →Dopamine-producing nerve cells are being evaluated for selected movement disorders. Early results cannot show lasting benefit or a cure. NCT07617012 · Phase 1 · Not yet recruiting · checked 12 Nov 2026
Study record →Gene delivery to the inner ear is being studied for specific genetic deafness, such as OTOF-related hearing loss. It is not a treatment for age-related hearing loss or tinnitus. NCT06722170 · Phase not stated · Recruiting · checked 12 Nov 2026
Study record →Companies are developing investigational cell products for retinitis pigmentosa. Approval to start a trial does not mean it is recruiting or that sight will improve.
Small studies are testing CAR-T in severe lupus that has not responded to other treatment. They carry significant immune-related risks. NCT06513429 · Phase not stated · Recruiting · checked 12 Nov 2026
Study record →One implanted device to restore hand grasp after cervical spinal cord injury was approved in China in 2026 (see our treatment page). More advanced systems remain experimental.
Already approved: in June 2026 China approved a CAR-T therapy for CLDN18.2-positive stomach cancer. See Cell therapy for solid tumours.
Tell us which condition or technology interests you. We can share publicly available information and, where appropriate, ask a licensed research centre whether an authorized assessment is possible. We cannot promise access to any study or any benefit.
Last reviewed 10 November 2026. Study status changes often; check the official registry and the study team before making any plans.
Sino Health Link is an independent coordination service, not a hospital. We do not diagnose, prescribe or treat. Licensed doctors make all medical recommendations and decisions with you.
